We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...

This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments. For 2025, GSK expects turnover ...

plus over 4 billion pound sterling in combined peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines portfolio ...

Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains. The content of this article is provided for information purposes only and is ...

GSK (GSK.L) shares ended 2024 on a sour note after what proved to be a rollercoaster year. The pharma giant dropped 7% over the 12 months, as worries over Zantac litigation and potential shake-ups in ...